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Objective. In diffuse parenchymal lung diseases,
the evolution of pulmonary fibrosis is often devastating
and may result in death. In this study the role of CCL18
as a biomarker of disease activity in idiopathic intersti-
tial pneumonias (IIPs) and systemic sclerosis (SSc)
with lung involvement was evaluated.
Methods. CCL18 was assessed in supernatants of
cultured bronchoalveolar lavage (BAL) cells as well as
BAL fluid and serum samples from 43 patients with
IIPs, 12 patients with SSc, and 23 healthy control
subjects. Concentrations of CCL18 were measured by
enzyme-linked immunosorbent assay, and expression of
CCL18 was assessed by flow cytometry.
Results. CCL18 concentrations were statistically
significantly increased in all patients with fibrotic lung
diseases. Spontaneous CCL18 production by BAL cells
was negatively correlated with total lung capacity and
the diffusion capacity for carbon monoxide, whereas
there was a positive correlation of CCL18 concentra-
tions with BAL neutrophil and eosinophil cell counts.
Flow cytometry revealed an increase in the percentage of
CCL18-positive alveolar macrophages and an increase
in the CCL18 fluorescence intensity per cell in patients
with fibrotic lung diseases. In a cohort of patients who
were followed up for at least 6 months (n  40), a close
negative correlation was observed between changes in
the predicted total lung capacity and changes in CCL18
serum concentrations.
Conclusion. These findings suggest that CCL18
production by BAL cells and serum CCL18 concentra-
tions reflect pulmonary fibrotic activity in patients with
IIPs and those with SSc. Monitoring changes in CCL18
production might be an extraordinarily useful tool in
clinical practice and in studies aimed at evaluating new
approaches for treatment of fibrotic lung diseases.
Fibrotic lung diseases have recently been given a
new classification as idiopathic interstitial pneumonias
(IIPs) and have been categorized into different subtypes,
such as usual (UIP), nonspecific (NSIP), and desquama-
tive (DIP) interstitial pneumonias as well as cryptogenic
organizing pneumonia (COP) (1). However, fibrotic
remodeling of lung parenchyma is also a main feature of
lung involvement in patients with rheumatic diseases.
Approximately half of all diagnosed cases with the
typical histologic pattern of IIPs are associated with a
rheumatic disease (2). Therefore, lung involvement in
patients with rheumatic diseases can be identified by the
same histologic and radiologic patterns as described in
patients with IIPs, and is not distinguishable from the
idiopathic variants. For example, in patients with sys-
temic sclerosis (SSc), lung involvement may occur in a
pattern typical of NSIP, but could also resemble that of
UIP (2).
In patients whose disease is associated with fi-
brotic lung remodeling, including patients with SSc as
well as patients with radiologic types III and IV sarcoid-
osis, hypersensitivity pneumonitis, or idiopathic pulmo-
nary fibrosis (IPF) (UIP pattern), we recently found that
a common feature is shared: the phenotype of the
alveolar macrophages in these patients is characterized
by alternative activation with exaggerated production of
the CC chemokine ligand CCL18 (3). In addition,
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increased expression of CCL18 messenger RNA
(mRNA) has been described in bronchoalveolar lavage
(BAL) cells from patients with SSc (4). Recently,
Kodera et al (5) observed increasing CCL18 concentra-
tions in the serum of patients with SSc, indicating the
presence of pulmonary fibrotic remodeling. Further-
more, their findings suggest that CCL18 might serve as
an indicator of disease activity, since the authors ob-
served decreasing CCL18 concentrations in 20 patients
with SSc after treatment with immunosuppressive
agents.
Our previous studies, along with those by Atamas
et al (6), have shown that the increased production of
CCL18 by alternatively activated alveolar macrophages
in patients with pulmonary fibrosis promotes the pro-
duction of collagen by lung fibroblasts (3). In these
patients, we observed a vicious circle in which the
interaction of alternatively activated alveolar macro-
phages and lung fibroblasts perpetuates the fibrotic
process (3). CCL18 is a chemokine that has thus far been
described only in primates and is abundantly produced
within the lung (7–9). Its receptor is not known, and only
myeloid-derived cells have been found to produce this
mediator, which was previously termed pulmonary and
activation-regulated chemokine (7–9).
Following the revised classification of the IIPs,
several large studies exploring new therapeutic strategies
for IPF and SSc have recently been published (10,11) or
are in progress. Very often, the results of the various
studies have been contradictory with regard to the
influence of the tested treatment schedule on pulmonary
function, mortality, or the 6-minute walk test (12,13). At
present there is no established biomarker that can
adequately reflect pulmonary fibrotic activity.
Given this background, we wondered whether
CCL18 can serve as a biomarker of disease activity in
patients with pulmonary fibrosis. We examined a total of
43 patients with either IPF, DIP, NSIP, or COP and 12
patients with SSc, as well as 23 healthy control subjects.
Our results reveal that CCL18 is abundantly expressed
in the culture supernatants of BAL cells and the BAL
fluid and sera from patients whose pulmonary fibrosis is
histologically proven. Our results also show that concen-
trations of CCL18 in BAL fluid are highly correlated
with known markers of disease severity. In addition, in
the course of disease in 40 patients with different IIPs or
SSc, we observed a close negative correlation between
changes in the total lung capacity and changes in the
serum CCL18 concentrations. It therefore appears that
the concentration of CCL18 in the serum may serve as
an indicator of pulmonary disease activity in patients
with pulmonary fibrosis, in both its idiopathic and its
rheumatic forms.
PATIENTS AND METHODS
Subjects. Sixteen patients with IPF (UIP pattern), 12
patients with SSc and proven lung involvement, 7 patients with
NSIP, 10 patients with DIP, and 10 patients with COP were
studied. All patients displayed a typical histologic pattern of
pulmonary fibrosis, as determined by transbronchial or video-
assisted thoracoscopic biopsy. The diagnosis in all patients was
confirmed as being in accordance with the American Thoracic
Society/European Respiratory Society (ATS/ERS) criteria for
IIPs (1) and the American College of Rheumatology (for-
merly, the American Rheumatism Association) criteria for SSc
(14), by clinical evaluation, high-resolution computed tomo-
graphy (HRCT), histologic assessment, and laboratory tests.
None of the patients with IIPs had rheumatic diseases. All
patients with SSc tested positive for anti–DNA topoisomerase
I autoantibodies and were found to have a histologic pattern
typical of NSIP on HRCT and histologic examination of the
lung biopsy tissue. Twenty-three healthy volunteers served as
the control group. Patients’ characteristics, including age, sex,
and pulmonary function data, as well as the distribution of the
BAL cell subsets are shown in Table 1.
The study was approved by the local ethics committee.
Table 1. Characteristics and distribution of BAL cells in the study subjects*
Characteristic Control IPF NSIP COP DIP SSc
Age, years 36.0  16.9 67.1  14.1 60.1  15.3 61.0  14.4 54.8  8.7 66.2  13.4
Sex, no. male/no. female 13/10 13/3 4/3 7/3 8/2 3/9
TLC, % of predicted 98.8  10.0 61.2  11.1 58.1  12.6 80.7  18.1 91.2  7.9 72.0  20.5
DLCO, % of predicted 90.0  14.0 58.7  19.6 46.3  13.4 74.2  22.4 61.8  8.2 63.3  19.0
Differential BAL cell count, %
Macrophages 92  7 71  15 66  16 57  17 93  5 69  17
Lymphocytes 7  7 13  9 15  17 35  14 2  1 18  10
Neutrophils 1  1 10  8 13  7 3  4 3  3 9  10
Eosinophils 0  0 6  7 4  4 2  5 1  3 3  2
* Except where indicated otherwise, values are the mean  SD. BAL  bronchoalveolar lavage; IPF  idiopathic pulmonary fibrosis; NSIP 
nonspecific interstitial pneumonia; COP  cryptogenic organizing pneumonia; DIP  desquamative interstitial pneumonia; SSc  systemic sclerosis;
TLC  total lung capacity; DLCO  diffusion capacity for carbon monoxide.
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Pulmonary function tests were routinely performed using
standard methods, in accordance with the ATS recommenda-
tions (15). The diffusion capacity for carbon monoxide (DLCO)
was measured by a single-breath method using a gas mixture of
0.2% CO and 8% helium, with correction for hemoglobin.
In addition, serum samples and pulmonary function
data were collected from a separate cohort of 40 patients with
pulmonary fibrosis whose condition was attributable to various
interstitial lung diseases (8 patients with COP, 5 patients with
NSIP, 17 patients with IPF, 5 patients with DIP, and 5 patients
with SSc). These patients were followed up for at least 6
months, during which at least 4 serum samples and 4 sets of
pulmonary function data were obtained from each patient.
Serum samples were tested in duplicate. During this observa-
tion period, patients received various drugs, including steroids,
acetylcysteine, azathioprine, and cyclophosphamide. The pa-
tients were separated into 3 groups according to the ATS/ERS
criteria for IIPs (1), categorized by whether patients had
progressive, stable, or improving disease. Any improvement
during the observation period was defined as an increase in
total lung capacity of more than 10%, while deterioration was
defined as a decrease in total lung capacity of more than 10%.
For comparisons, changes in total lung capacity and changes in
CCL18 concentrations were calculated by subtracting the data
at the beginning of the observation period from the data at the
end of the observation period.
Preparation of BAL cells and cell culture. Bronchos-
copy, BAL, and culture of BAL cells were performed using
standard techniques as previously described (16,17). In detail,
BAL cells (1  106 cells/ml) were placed in 24-well culture
plates in RPMI (Gibco, Karlsruhe, Germany) with 2% heat-
inactivated human AB serum and antibiotics (50 units/ml
penicillin and 50 g/ml streptomycin; Biochrom, Berlin, Ger-
many) in a humidified atmosphere containing 5% CO2 at 37°C
for 24 hours. At the end of the culture period, supernatants
were harvested and stored at 70°C until assayed for CCL18
concentrations. The viability of the cells was determined by
Trypan blue exclusion, and always exceeded 95%. The mean
frequency of each subset of BAL cells in the study groups is
shown in Table 1; data were not corrected for differing cell
cytologic features.
Differential BAL cell count. BAL cells were stained
with May-Grünwald stain. The differential cell count for each
subset of BAL cells was then determined by counting at least
200 cells on the cell smear.
Flow cytometry. Freshly isolated BAL cells from
healthy volunteers and from patients with pulmonary fibrosis
were fixed in 4% paraformaldehyde and stained using biotin-
ylated goat anti-human CCL18 antibody and streptavidin/
phycoerythrin (DakoCytomation, Carpinteria, CA). Not all
patients were included in this experiment. Cells were analyzed
by flow cytometry (FACSCalibur; BD Biosciences, San Jose,
CA). The percentage of CCL18-positive cells was determined
using isotype-matched biotinylated antibodies as a control.
Results are expressed as the relative fluorescence intensity,
calculated by subtracting the intensity of CCL18 staining from
the intensity of isotype-matched control antibody staining.
Enzyme-linked immunosorbent assay (ELISA).
CCL18 was quantified using a DuoSet ELISA Development
System kit (R&D Systems Europe, Abingdon, UK). The
detection limit for the CCL18 ELISA was 7 pg/ml. For
duplicate samples, an intraassay coefficient of variation (CV)
of 10% and an interassay CV of 20% were accepted.
Results were not adjusted for the differential BAL cell count.
Statistical analysis. Data on CCL18 are expressed as
the median (interquartile range). Statistical comparisons be-
tween experimental and control data in the in vitro studies
were made by analysis of variance with post hoc Fisher’s
protected least significant difference test. Correlations were
determined using a simple regression model. Prior to these
analyses, binominal distribution data were logarithmically
transformed. P values less than 0.05 were considered signifi-
cant.
Figure 1. Spontaneous production of CCL18 by bronchoalveolar la-
vage (BAL) cells (A) and concentrations of CCL18 in BAL fluid (B)
and serum (C) from patients with idiopathic interstitial pneumonias
(desquamative interstitial pneumonia [DIP; n  10], cryptogenic
organizing pneumonia [COP; n  10], nonspecific interstitial pneumo-
nia [NSIP; n  7], and idiopathic pulmonary fibrosis [IPF; usual
pattern; n  16]), patients with systemic sclerosis (SSc) with lung
involvement (n  12), and healthy volunteers as controls (n  23).
Values are presented as box plots, where the boxes represent the 25th
to 75th percentiles, the lines within the boxes represent the median,
and the lines outside the boxes represent the 10th and 90th percentiles.
  P  0.05;   P  0.001, versus controls. CCM  conditioned
culture medium.
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RESULTS
Marked increase in CCL18 production by BAL
cells derived from patients with pulmonary fibrosis.
BAL cells derived from patients or healthy volunteers
were cultured for 24 hours in culture medium. Sponta-
neous CCL18 production in the cell culture supernatants
was measured by ELISA. BAL cells from patients with
IPF, patients with NSIP, and patients with SSc produced
the highest concentrations of CCL18 (Figure 1A), with
100-fold higher concentrations in these cells than in
those from healthy volunteers (P  0.001). BAL cells
from patients with COP and patients with DIP also
showed an increased production of CCL18 (P  0.05)
(Figure 1A), but the median concentrations of CCL18 in
these patients were statistically significantly lower than
in the cohorts of patients with IPF or NSIP (P  0.05)
(Figure 1A).
Increased CCL18 concentrations in BAL fluid
and serum from patients with IIPs and patients with
SSc. The concentrations of CCL18 in BAL fluid and
serum (Figure 1B) resembled that described for BAL
cells. CCL18 concentrations in BAL fluid were highest
in patients with IPF, those with NSIP, and those with SSc
(Figure 1B). The CCL18 concentrations in patients with
IPF and patients with NSIP were also up to 100-fold
higher than in healthy controls. Four cohorts of patients
with fibrotic lung tissue remodeling (IPF, NSIP, COP,
and SSc) showed a statistically significant increase in
CCL18 concentrations in the BAL fluid. In addition,
there was a close correlation between the CCL18 con-
centrations measured in the BAL fluid and those in the
conditioned medium of BAL cells cultured for 24 hours
(r  0.64, P  0.0001).
With regard to serum concentrations, CCL18 was
significantly increased in 3 cohorts of patients with
fibrotic lung tissue remodeling (NSIP, IPF, and SSc)
(Figure 1C). There was a close correlation between the
CCL18 concentrations in the serum and those in the
BAL fluid (r  0.64, P  0.0001) and between the serum
concentrations and those in the conditioned BAL cell
culture medium (r  0.56, P  0.0001).
Increase in the percentage of CCL18-positive
alveolar macrophages and CCL18 fluorescence intensity
per cell in patients with fibrotic lung diseases. Not all
patients were included in the flow cytometry experi-
ments. Flow cytometric analyses of BAL cells from
patients and healthy controls revealed that only large
BAL cells stained positive for CCL18. These cells could
be identified as alveolar macrophages on the basis of cell
granularity and size. BAL lymphocytes showed no stain-
ing for CCL18 (Figure 2A). We observed an increase in
the percentage of CCL18-positive alveolar macrophages
and in the CCL18 fluorescence intensity per cell in
patients with fibrotic lung diseases in comparison with
healthy controls (Figures 2G and H).
Close correlation of spontaneous CCL18 produc-
tion by BAL cells and serum CCL18 concentrations with
BAL neutrophil and BAL eosinophil cell counts. BAL
neutrophil and BAL eosinophil cell counts are estab-
lished indicators of the extent of fibrotic remodeling in
the lavaged lung area. Furthermore, both are known to
have prognostic value in patients with pulmonary fibro-
sis. We observed a close correlation between spontane-
Figure 2. Flow cytometric analyses of spontaneous CCL18 expres-
sion. Immunostaining for CCL18 was performed on bronchoalveolar
lavage (BAL) lymphocytes from a patient with idiopathic pulmonary
fibrosis (IPF) (A) and on BAL macrophages from a patient with IPF
(B), a patient with cryptogenic organizing pneumonia (COP) (C), a
patient with nonspecific interstitial pneumonia (NSIP) (D), a patient
with systemic sclerosis (SSc) (E), and a healthy volunteer (F). Findings
in A–F are representative of the flow cytometry results in all subjects.
In addition, the percentage of CCL18-positive alveolar macrophages
(G) and the relative fluorescence intensity for CCL18 on alveolar
macrophages (H) were determined in 10 healthy control subjects, 5
patients with COP, 7 patients with IPF, 5 patients with NSIP, and 5
patients with SSc with lung involvement. Values in G and H are
presented as box plots, where the boxes represent the 25th to 75th
percentiles, the lines within the boxes represent the median, and the
lines outside the boxes represent the 10th and 90th percentiles.  
P  0.05;   P  0.005. PARC-PE  pulmonary and activation-
regulated chemokine (CCL18) with phycoerythrin staining.
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ous CCL18 production by BAL cells and both the BAL
neutrophil cell count (r  0.73, P  0.0001) and the BAL
eosinophil cell count (r  0.63, P  0.0001) (Figures 3A
and B). There was a weak correlation between the
percentage of alveolar macrophages and spontaneous
CCL18 production by BAL cells (r  0.38, P  0.0001),
and there was no correlation between the percentage of
BAL lymphocytes and spontaneous CCL18 production
by BAL cells. Similar to the observations in BAL cell
culture medium, there was a correlation between CCL18
concentrations in the serum and both the BAL neutrophil
cell count (r  0.58, P  0.0001) and BAL eosinophil cell
count (r  0.62, P  0.0001) (results not shown).
Correlation of serum CCL18 concentrations with
pulmonary function data. A close negative correlation
was observed between the production of CCL18 by BAL
cells and the total lung capacity (r  0.66, P  0.0001)
(Figure 4A). In addition, there was a close negative
correlation between the DLCO and the production of
CCL18 by BAL cells (r  0.66, P  0.0001) (Figure
4B). Furthermore, there was a negative correlation
between CCL18 concentrations in the serum and both
the total lung capacity (r  0.52, P  0.0001) and the
DLCO (r  0.36, P  0.0044) (results not shown).
Serum CCL18 concentration as an indicator of
fibrotic activity. We collected serum samples and pul-
monary function data, in parallel, from an additional
cohort of 40 patients with pulmonary fibrosis. In these
patients, there was a close negative correlation between
Figure 3. Correlation of spontaneous production of CCL18 by bron-
choalveolar lavage (BAL) cells with BAL neutrophil (A) and BAL
eosinophil (B) cell counts in the total study cohort. Circles indicate
individual values. CCM  conditioned culture medium.
Figure 4. Negative correlation of CCL18 concentrations in bron-
choalveolar lavage (BAL) cell supernatants with the total lung capacity
(A) and the diffusion capacity for carbon monoxide (DLCO) (B) in the
total study cohort. For normalization, CCL18 concentrations are
depicted on a logarithmic scale. CCM  conditioned culture medium.
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the change in total lung capacity and the change in
serum production of CCL18 (r  0.78, P  0.0001)
(Figure 5A). Patients whose total lung capacity im-
proved over the followup period (at least 6 months) had
decreasing serum CCL18 concentrations. In these pa-
tients, the change in CCL18 production was expressed as
a negative value, because serum CCL18 concentrations
at the beginning were higher than serum CCL18 con-
centrations at the end of the observation period.
We also separated these 40 patients into 3 differ-
ent groups on the basis of the ATS/ERS criteria, with
categories according to whether the patients had pro-
gressive, stable, or improving disease (1). The serum
CCL18 concentrations in patients with progressive dis-
ease increased during the observation period and were
significantly different from those in patients with stable
or improving disease (Figure 5B).
DISCUSSION
Pulmonary fibrosis represents a final pathway of
various pulmonary diseases, including lung involvement
in rheumatic diseases. In a recent report we showed that
different interstitial lung diseases, such as radiologic
types III and IV sarcoidosis, hypersensitivity pneumoni-
tis, and IPF, share the up-regulation of CCL18 produc-
tion as a common mechanism, and that a vicious circle
involving macrophages and fibroblasts and their prod-
ucts, CCL18 and collagen, perpetuates pulmonary fibro-
sis (3). In this study we have shown that CCL18 is
abundantly produced by BAL cells from patients with
IIPs and patients with SSc. Production of CCL18 by
BAL cells was correlated with pulmonary function re-
sults and BAL neutrophil cell counts, which are both
known markers of disease progression. In addition, in
another group of 40 patients with fibrotic lung disease,
we observed an extraordinarily close correlation be-
tween the course of total lung capacity and changes in
serum CCL18 levels.
Our data clearly demonstrate that CCL18 pro-
duction by BAL cells is markedly enhanced in patients
with fibrotic lung disease in the IIPs or SSc. BAL cells
from patients with IPF (UIP pattern), patients with
NSIP, or patients with SSc produced up to 100-fold more
CCL18 than did the BAL cells of healthy control sub-
jects. In addition, BAL cells from patients with other
diseases associated with pulmonary fibrosis, such as
COP or DIP, produced a higher level of CCL18 than was
found in controls. We have recently shown that there is
a strong link between CCL18 production and the evolu-
tion of pulmonary fibrosis in such different diseases as
sarcoidosis, IPF, and hypersensitivity pneumonitis. We
herein show that there is also an increase in CCL18
protein production in IIPs such as DIP, NSIP, COP, and
IPF (UIP pattern), as well as in SSc. An increase in
CCL18 mRNA expression in patients with SSc (4) and
patients with IPF (18) has been described previously.
However, we are the first to comprehensively describe
CCL18 production by BAL cells in a broad spectrum of
fibrotic lung diseases. In a recent study, we found that
CCL18 produced by alveolar macrophages enhances
Figure 5. Close correlation between the course of serum concentra-
tions of CCL18 and course of total lung capacity in 40 patients with
various interstitial lung diseases associated with pulmonary fibrosis. A,
Correlation between changes in total lung capacity and changes in
serum CCL18 concentrations during the period of observation. B,
Correlations with serum CCL18 concentrations among patients
grouped according to the course of pulmonary function during the
observation time, classified by improvement, stabilization, or deterio-
ration of disease using the American Thoracic Society/European
Respiratory Society criteria (1). Values in B are presented as box plots,
where the boxes represent the 25th to 75th percentiles, the lines within
the boxes represent the median, and the lines outside the boxes
represent the 10th and 90th percentiles.   P  0.05 versus patients
with stable disease.
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collagen production by lung fibroblasts (3), and con-
versely, fibroblast production of collagen up-regulates
CCL18 production by alveolar macrophages. The
present study demonstrates that this vicious circle is a
common mechanism in all tested fibrotic lung diseases.
Thus, our data suggest that an increase in CCL18
production by BAL cells indicates the evolution of
pulmonary fibrotic remodeling.
CCL18 concentrations were also highly increased
in the BAL fluid from all tested patient cohorts with
fibrotic lung disease. In patients with IPF, SSc, or NSIP,
CCL18 concentrations in BAL fluid were up to 100-fold
higher than is considered normal, similar to the results
obtained on CCL18 production by BAL cells. Consistent
with our previous findings and those by Pardo et al
(3,18), we were able to show, by in situ hybridization and
immunohistochemistry and by assessment of isolated
cells, that CCL18 is mainly produced by alveolar macro-
phages. The close correlation between the levels of
CCL18 in BAL fluid and those in BAL cell cultures
suggests that the main CCL18-producing cells can be
recovered by BAL. According to previously published
results from our group (3), flow cytometric analysis of
BAL cells revealed that only alveolar macrophages, and
not BAL lymphocytes, produce CCL18. The difference
in CCL18 production between patients and controls is
caused by an increase in the percentage of CCL18-
producing cells as well as an increase in the CCL18
production per cell in patients with fibrotic lung dis-
eases.
Several factors could have an influence on the
observed differences in CCL18 production by BAL cells
between different patient cohorts. We have previously
shown that collagen itself up-regulates CCL18 produc-
tion by alveolar macrophages, in a concentration-
dependent manner. Therefore, differences in fibrotic
activity, which is tantamount to increased collagen pro-
duction and fibroblast proliferation, might be responsi-
ble for the observed differences in CCL18 production
between patient cohorts. Since there was heterogeneity
in disease severity, particularly in the cohort of patients
with SSc, this might also explain the broad range of
CCL18 production within the patient cohorts.
In this context we wondered whether CCL18
levels in BAL cell supernatants and in serum were
indicators of disease severity. To test this, we analyzed
the relationship between parameters of pulmonary func-
tion and differential BAL cell counts. We observed a
negative correlation between CCL18 concentrations in
BAL cell supernatants or serum and the total lung
capacity, and a negative correlation between CCL18
concentrations and the DLCO. Both of these pulmonary
function markers are known to reflect disease severity
and are associated with the risk of death in patients with
pulmonary fibrosis (19–22). In addition, there was a
correlation between CCL18 concentrations in BAL cell
supernatants or serum and BAL neutrophil and eosino-
phil cell counts, which have been described as markers of
disease progression and fibrotic activity in patients with
pulmonary fibrosis and SSc (23–27). The possibility that
CCL18 has a direct influence on peripheral blood neu-
trophils via its chemotactic activity was recently excluded
(28). CCL18 is described as a chemokine capable of
attracting naive T cells, activated T cells, monocytes,
eosinophils, and dendritic cells (9,28,29). Nevertheless,
despite the correlations with BAL eosinophil cell counts,
there was no correlation between BAL cell lymphocyte
counts and concentrations of CCL18 in BAL cell super-
natants, and there was only a weak correlation with BAL
macrophage cell counts.
We showed a close correlation between the con-
centrations of CCL18 in BAL fluid and those in serum.
Interestingly, CCL18 levels in the serum were similarly
high, and detectable within the 100-ng range. This
correlation between CCL18 levels in BAL fluid and
those in the serum from all examined disease groups
suggests that the level of CCL18 production within the
lung is reflected in the serum production of CCL18.
However, we cannot exclude the possibility that other
factors might influence CCL18 levels in the serum. In
our experiments, alveolar macrophages produced 100-
fold more CCL18 compared with freshly isolated mono-
cytes. None of our patients had a disease, such as atopic
dermatitis (30) or Gaucher disease, that is known to be
associated with increased CCL18 serum levels (31). The
increase in serum CCL18 concentrations in patients with
fibrotic lung diseases might be associated with multiple
mechanisms. First, there might be spillover from the
lung. Second, results from several studies have suggested
that there is also an increase in serum collagen concen-
trations in patients with fibrotic lung disease (32,33). We
have shown that macrophages produce more CCL18
following stimulation with collagen (3). Therefore, it
might be possible that the increase in serum collagen
concentrations will cause an increase in CCL18 produc-
tion by extrapulmonary macrophages that are exposed
to serum collagen. Furthermore, it is tempting to spec-
ulate that there is systemic aberrant CCL18 production
by macrophages in patients with fibrotic lung diseases.
This issue requires further study.
In other experiments, we analyzed the relation-
ship between serum CCL18 concentrations and disease
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progression. We observed a close negative correlation
between the changes in serum CCL18 concentrations
and the changes in total lung capacity. This effect was
observed regardless of the given therapy. More pre-
cisely, in patients in whom pulmonary function improved
with the use of steroids (with or without further immu-
nosuppressive therapy), CCL18 levels decreased. In
contrast, in patients with IPF or SSc whose pulmonary
function declined despite the use of therapy with immu-
nosuppressants such as steroids, CCL18 serum concen-
trations increased. This finding suggests that changes in
serum CCL18 concentrations reflect disease activity
rather than the severity of the disease. In patients in
whom disease activity was obviously ameliorated by
steroids, such as in patients with COP, the CCL18
concentrations dramatically decreased. Therefore, se-
rum CCL18 levels could serve as an indicator of disease
activity in patients with pulmonary fibrosis who are
being treated with a distinct drug regimen.
The observed correlation between the course of
predicted total lung capacity and changes in serum
CCL18 concentrations was extraordinarily close, with a
correlation coefficient of 0.78. To our knowledge, the
correlation between other known serum markers, such
as KL-6, interleukin-8, or surfactant D, and pulmonary
function data is far lower. Recently, Kodera et al (5)
showed that serum CCL18 concentrations in patients
with SSc were indicative of the evolution of pulmonary
fibrosis, and that serum CCL18 levels better reflected
the pulmonary outcome in patients with SSc than did,
for instance, the levels of KL-6. In 21 patients with SSc
who showed an improvement in their fibrosis activity
score on HRCT following immunosuppressive therapy,
Kodera et al (5) found decreased serum CCL18 concen-
trations in parallel with a change in pulmonary fibrotic
activity in all but 1 of the patients. Combining these data
with our findings, we propose that increasing serum
CCL18 concentrations can be used as an indicator of the
evolution of fibrotic lung remodeling, and that serum
CCL18 concentrations reflect the fibrotic lung activity in
patients with pulmonary fibrosis independent of the
cause of the disease.
In conclusion, our studies show that the produc-
tion of CCL18 within the lung is dramatically up-
regulated in patients with IIPs and in those with SSc,
both of which are diseases known to be associated with
fibrotic lung tissue remodeling. We demonstrate that
there is a close correlation between CCL18 production
and other known factors of disease progression in pa-
tients with pulmonary fibrosis. Serum CCL18 concentra-
tions are strongly correlated with CCL18 production by
BAL cells. In contrast to an approach utilizing BAL
neutrophil cell counts, serum CCL18 concentrations are
easily determined and repeatable. Furthermore, in con-
trast to pulmonary function tests, no cooperation of the
patient is needed for determinations of CCL18. We
believe that repeated measurements of serum CCL18
concentrations can provide additional and valid infor-
mation. Monitoring serum CCL18 concentrations in
patients with rheumatic diseases might reveal the evolu-
tion of pulmonary fibrotic remodeling. Furthermore,
monitoring serum CCL18 concentrations during the
course of the disease and at the time when pulmonary
fibrosis is already established might be an extraordinarily
useful tool in clinical practice and in studies evaluating
new antifibrotic approaches to treatment.
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